Wilmer Alexander
Department of General Internal Medicine, Medical Intensive Care Unit, Gasthuisberg University Hospital, Catholic University of Leuven, 3000 Leuven, Belgium.
Eur J Intern Med. 2004 Aug;15(5):274-280. doi: 10.1016/j.ejim.2004.06.004.
In intensive care medicine, severe acute pancreatitis (SAP) remains a very challenging disease with multiple complications and high mortality. The main pathophysiological mechanisms determining outcome are an uncontrolled systemic hyperinflammatory response early on and infection of pancreatic necrosis later on in the disease process. Despite a better understanding in recent years of the mechanisms and the mediators involved in the hyperinflammatory response, there is, as yet, no generally recognized specific treatment for this disease. Since early identification and aggressive treatment of associated organ dysfunction can have a major impact on outcome, early assessment of prognosis and severity is important. The evidence available indicates that patients with severe acute pancreatitis do not benefit from therapy with available antisecretory drugs or protease inhibitors. Supportive therapy, such as vigorous hydration, analgesia, correction of electrolyte and glycemia disorders, and pharmacological or mechanical support targeted at specific organs, is still the mainstay of therapy. In spite of meager evidence, prophylactic antibiotics with good penetration in pancreatic tissue are recommended in severe acute pancreatitis. Enteral nutrition via a nasojejunal tube has become the preferred route of feeding. Most patients with sterile necrosis do not benefit from surgical intervention. In patients with proven infection of pancreatic tissue, surgery is necessary. Percutaneous, radiological drainage techniques may eventually become an alternative form of drainage in selected patients.
在重症监护医学中,重症急性胰腺炎(SAP)仍然是一种极具挑战性的疾病,伴有多种并发症且死亡率高。决定预后的主要病理生理机制是疾病早期不受控制的全身高炎症反应以及后期胰腺坏死感染。尽管近年来对高炎症反应所涉及的机制和介质有了更好的理解,但对于这种疾病,目前尚无普遍认可的特异性治疗方法。由于早期识别并积极治疗相关器官功能障碍对预后有重大影响,因此早期评估预后和严重程度很重要。现有证据表明,重症急性胰腺炎患者无法从现有的抑分泌药物或蛋白酶抑制剂治疗中获益。支持性治疗,如积极补液、镇痛、纠正电解质和血糖紊乱以及针对特定器官的药物或机械支持,仍然是治疗的主要手段。尽管证据不足,但对于重症急性胰腺炎,建议使用在胰腺组织中具有良好渗透性的预防性抗生素。经鼻空肠管进行肠内营养已成为首选的喂养途径。大多数无菌性坏死患者无法从手术干预中获益。对于已证实胰腺组织感染的患者,手术是必要的。经皮放射引流技术最终可能成为部分特定患者的替代引流方式。